Project Team Leader and Associate Director of In Vivo Pharmacology. Developing precision gene therapies for pediatric CNS disorders with a focus on genomics-driven precision medicine to overcome key limitations of viral gene therapy.

Developing senolytic therapies to prevent fibrosis and reduce inflammation in age-related disease• Managed in vivo pharmacology team of researchers (RAs, Associate Scientists and PhD-level Scientists) to characterize lead compounds and conduct preclinical studies in mouse models of neuro, lung, liver, ocular disease and atherosclerosis.• Neuro and Liver Project Team Leader: Developed team strategy, advised functional leaders within team efforts (in vivo, in vitro, medchem, disease hypothesis and discovery technologies), presented regular updates to Executive Team on timelines and progress made • Lung Project In Vivo Functional Lead: worked with Team Leader to implement strategy for in vivo characterization of lead compounds in animal models of lung disease• Atherosclerosis In Vivo Exploratory Lead: worked with Team Leader to implement strategy for POC studies and in vivo characterization of lead compounds in an animal model of atherosclerosis.• Managed husbandry and characterization of key genetically engineered mouse models (GEMMs)• Full member of Unity IACUC: worked closely with Veterinarian and Vivarium manager to execute functions of IACUC

Engineering targeted growth factors for regenerative medicine • Led in vivo model selection and development strategy to build PK/PD relationships and evaluate efficacy of targeted growth factors for indications in kidney, heart and brain. Wrote and reviewed IACUC protocols.• Managed external work involving preclinical animal models and IND-enabling toxicology studies conducted at CROs• Performed both in-life and subsequent assay development to characterize lead protein therapeutics.• Organized and led Pre-IND meeting for SGF1 with FDA Division of Cardiovascular and Renal products

Interneuron Function and Differentiation in Mouse Models of Neurological DiseaseAdvisor: Arturo Alvarez-Buylla• Evaluated the safety and efficacy of interneuron precursor transplantation in mouse models of neurological disease. • Investigated modification of inhibitory circuits as a therapeutic approach in a DISC1 mouse model of neuropsychiatric disease. • Managed and coordinated correspondence and biannual progress reports for CIRM grant CIRM TR2-01749 “Inhibitory Nerve Cell Precursors: Dosing, Safety and Efficacy."